

Signant SmartSignals® Solutions for Prostate Cancer

MAKING STRIDES TOWARDS NEW TREATMENTS **ONE** **STUDY AT A TIME**



Prostate cancer is the most common cancer among men, but it can be treated successfully. Signant Health applies decades of clinical experience in oncology studies and deep therapeutic expertise with prostate cancer to facilitate the approval of new therapies and treatments. Coupled with clinical trial technology solutions in our SmartSignals suite, we optimize the quality and reliability of clinical data, helping study teams identify new therapies sooner.

CAPTURE RELIABLE COA DATA & LAUNCH QUICKLY

Ensure your trials generate reliable patient-reported outcomes data using our comprehensive eCOA solutions. Built-in study design templates and instrument libraries enable rapid setup and launch, while our clinical and eCOA science experts ensure your trials are optimized for robust, accurate endpoint data.

PREVENT WASTE AND REDUCE SHIPMENTS & RETURNS

Prostate cancer studies often involve multiple patient cohorts and complex dosing schedules. Another variable adding complexity, investigational products for prostate cancer studies can be expensive as well as limited in supply and shelf life.

Signant's RTSM system utilizes unique algorithms to implement complex randomization schemes rapidly as well as optimize lot usage and efficiency. We support your study with a project team of multidisciplinary clinical science and operations experts from launch to closeout.

INCREASE PATIENT COMPREHENSION & EASE BURDENS FOR SITES & PATIENTS

Oncology studies are complex and treatments carry risks that should be understood by well-informed patients. Signant's eConsent solution improves comprehension and patient experience while providing sites with important version control features that ensure up-to-date informed consent forms.

COLLECT MORE COMPLETE PATIENT FUNCTION DATA

Help your study team collect accurate data about treatment effects on patient function. We integrate ActiGraph with our eCOA system to automatically collect sleep and activity data without additional burden on patients or sites. Study teams can view this data alongside COA data for a more complete evaluation of patient function.

DIGITIZE STUDIES FOR END-TO-END ACCURACY & VISIBILITY

While all of our solutions can be used as standalone tools, when combined they enhance the accuracy and efficiency of your prostate cancer study. Gain immediate access to electronic data for faster decision-making and improved regulatory inspections.

SIGNANT'S PROSTATE CANCER EXPERIENCE BY THE NUMBERS



I - IV
PHASES



105
TRIALS



8.5k
SITES



34k
PATIENTS



44
COUNTRIES



70
LANGUAGES

DRIVE BETTER RESEARCH OUTCOMES WITH SIGNANT SMARTSIGNALS SOLUTIONS

These solutions can be used individually or integrated together for a seamless, end-to-end digital experience.




eCOA

[LEARN MORE →](#)



eCONSENT

[LEARN MORE →](#)



RTSM

[LEARN MORE →](#)




TELEMEDICINE

[LEARN MORE →](#)

DISCUSS YOUR NEXT STUDY WITH US

Our global team of therapeutic area experts advise on all areas of the clinical development process, including:

- Clinical science and medicine
- Data analysis
- Regulatory
- Operations and trial administration
- Global logistics



[MEET THE EXPERTS →](#)